ScripIt was Groundhog Day on 2 February. That week, any pharmaceutical groundhogs would have emerged from their burrows, glanced at the shadows of tariffs, a global trade war and weak Chinese demand and sc
ScripAs the business development directors of big pharma companies flock to the annual J.P. Morgan Healthcare conference in San Francisco, important meetings will happen away from the conference ballrooms
ScripPharma Breaks Bread With Trump And RFK Jr But Will They Butt Heads? Donald Trump’s second term as US president does not begin until 20 January but pharma executives spent much of last year wondering w
In VivoWith the business year almost complete, a review of biopharmaceutical dealmaking showed that Novartis, in particular, enjoyed a very productive year with 21 transactions overall, including six acquisi